02 June 2015
Moscow, June, 2, 2015 – NovaMedica, a Russian pharmaceutical company, and Ferring Pharmaceuticals, a Swiss-based global biopharmaceutical company, have signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.
The product line includes established and soon-to-launch treatments for inflammatory bowel diseases: ulcerative colitis, Crohn's disease and bleeding from esophageal varices.
Employees of marketing and sales departments, medical advisors and representatives of NovaMedica will market and support the products in the Russian market.
“The agreement with Ferring opens up broad prospects for the development of products for the treatment of gastroenterological diseases, which are one of the most widely spread and significant medical problems in Russia. Through this collaboration, we will be able to offer Russian specialists and patients new solutions for treatment using effective medicines,” noted Fabrice Egros, the COO of NovaMedica.
“We are glad to collaborate with NovaMedica and believe that this company is the right choice because of its long-term strategy targeted at bringing innovative gastroenterological products to Russian patients,” said Kirill Litovchenko, General Manager of Ferring Russia.
NovaMedica is a Russian pharmaceutical company, established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, and RUSNANO, a Russian investment corporation, which implements the state policy on development of high-technology fields. The company’s strategy focuses on search, registration, and localization in Russia of intellectual property rights for innovative drugs and technologies, as well as development of a new high-technology pharmaceutical GMP manufacture. More details at: www.novamedica.com
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, obstetrics, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit: www.ferring.ruPrint
23 May 2022
23 May 2022
20 May 2022
20 May 2022